MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

At the two-and-a-half-year endpoint, the recurrence-free survival rate was 74.8% with the combination versus 55.6% for Keytruda. Moderna’s head of development for therapeutics and oncology ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

We're most bullish on Moderna and Merck's melanoma therapy, which we think has potential in a wide range of cancers in combination with Merck's Keytruda. The stellar efficacy and safety profile of ...

The vaccine also cut the risk of recurrence or death by 44%, versus Keytruda alone. Moderna has a solid pipeline of around 45 products in development, and nearly a quarter of them are expected to ...

This is a way for Moderna to take a seat at the table of personalized medicine. The company’s most advanced candidate is V940-Keytruda, which entered Phase III trials in 2024. The vaccine is ...

Moderna, Inc. (NASDAQ ... an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for ...